Dr. Kanwal Raghav, an oncologist at MD Anderson, discusses encouraging results from his phase II immunotherapy trial for peritoneal mesothelioma. He also emphasizes the importance of multidisciplinary teams and why patients should ask about clinical trials as soon as possible.